ArticleTrends in cancer2023
A new immuno-oncology target - SUMOylation.
Article in Trends in cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- SUMOylation in cancer: molecular mechanisms and therapeutic implications.Molecular cancer · 2026Review
- Exon-skipping antisense oligonucleotides targeting SUMO1 and SUMO2 demonstrate chemosensitizing effects in NSCLC cells in tissue culture.Research square · 2026Article
- Ginkgolic acid attenuates echinococcus granulosus infection-induced hepatic fibrosis by inhibiting Smad4 SUMOylation.PLoS neglected tropical diseases · 2026Article
- Targeting protein hyper-SUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma cross talk.Hepatology (Baltimore, Md.) · 2025Article
- The working mechanism of biomarkers related to sumoylation modification in coronary artery disease.Scientific reports · 2025Article
- Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment.Molecular cancer therapeutics · 2024Article
- Targeting SUMOylation with an injectable nanocomposite hydrogel to optimize radiofrequency ablation therapy for hepatocellular carcinoma.Journal of nanobiotechnology · 2024Article
- 1,10-phenanthroline inhibits sumoylation and reveals that yeast SUMO modifications are highly transient.EMBO reports · 2024Article
- Dysregulated gene expression of SUMO machinery components induces the resistance to anti-PD-1 immunotherapy in lung cancer by upregulating the death of peripheral blood lymphocytes.Frontiers in immunology · 2024Article
- Positioning SUMO as an immunological facilitator of oncolytic viruses for high-grade glioma.Frontiers in cell and developmental biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Immunotherapy has been a paradigm shift in cancer treatment to produce durable responses. Unfortunately, most cancers do not respond to current immunotherapies, and thus, exploring novel mechanisms is crucial. Emerging data now demonstrate that protein modification by the small ubiquitin-like modifiers (SUMO) is a novel target to activate antitumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.